文献速递肝病

粒细胞集落刺激因子联合TLR4抑制剂减轻小鼠慢加急性肝衰竭模型的炎症并促进肝再生

Combination of G-CSF and a TLR4 inhibitor reduce inflammation and promote regeneration in a mouse model of ACLF.
PubMed 文献 · J Hepatol · 2022-07-16

本研究在小鼠慢加急性肝衰竭(ACLF)模型中探讨TLR4拮抗剂TAK-242联合粒细胞集落刺激因子(G-CSF)的疗效。在脂多糖(LPS)模型中,单用G-CSF与显著死亡率相关(48小时66% vs 不用G-CSF 0%),加用TAK-242后死亡率降至0%并减轻肝细胞死亡、巨噬细胞浸润和炎症;在半乳糖胺(GalN)模型中,两药单用均减轻肝损伤,联用更有效。结论认为该联合方案可抑制炎症、促进肝再生并预防死亡,可能成为ACLF的潜在治疗选择。

要点

  • LPS诱导ACLF小鼠中,单用G-CSF 48小时死亡率为66%,不用G-CSF为0%。
  • G-CSF联合TAK-242使LPS模型死亡率降至0%,并减轻肝细胞死亡、巨噬细胞浸润和炎症。
  • GalN模型中G-CSF与TAK-242单用均减轻肝损伤,联用效果显著更优。

核心结论

  • TAK-242与G-CSF联用可抑制炎症、促进肝再生并预防ACLF模型死亡,可能成为ACLF的潜在治疗选择。

研究设计与样本

  • 研究采用两种小鼠ACLF模型:四氯化碳诱导慢性肝损伤后,分别给予脂多糖(LPS,肝外打击)或半乳糖胺(GalN,肝打击)。
  • 每日给予G-CSF和/或TAK-242;LPS模型治疗时长为24小时和5天,GalN模型为48小时。

主要发现

  • LPS诱导ACLF小鼠中,G-CSF治疗与显著死亡率相关(48小时66% vs 不用G-CSF 0%)。
  • G-CSF加用TAK-242后死亡率降至0%,并显著减少肝细胞死亡、巨噬细胞浸润和炎症。
  • GalN模型中,G-CSF和TAK-242单用均减轻肝损伤,但联用显著更有效。
  • 无论是否联用TAK-242,G-CSF治疗均与促再生和抗凋亡的STAT3通路激活相关。
  • LPS驱动ACLF以p21过表达为特征(提示肝衰老和抑制肝细胞再生);TAK-242减轻衰老效应,G-CSF与TAK-242联用显著增加肝细胞再生标志物。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Acute-on-chronic liver failure (ACLF) is characterised by high short-term mortality, systemic inflammation, and failure of hepatic regeneration. Its treatment is a major unmet medical need. This study was conducted to explore whether combining TAK-242, a Toll-like receptor-4 (TLR4) antagonist, with granulocyte-colony stimulating factor (G-CSF), could reduce inflammation whilst enhancing liver regeneration. METHODS: Two mouse models of ACLF were investigated. Chronic liver injury was induced by carbon tetrachloride; lipopolysaccharide (LPS) or galactosamine (GalN) were then administered as extrahepatic or hepatic insults, respectively. G-CSF and/or TAK-242 were administered daily. Treatment durations were 24 hours and 5 days in the LPS model and 48 hours in the GalN model. RESULTS: In a mouse model of LPS-induced ACLF, treatment with G-CSF was associated with significant mortality (66% after 48 hours vs. 0% without G-CSF). Addition of TAK-242 to G-CSF abrogated mortality (0%) and significantly reduced liver cell death, macrophage infiltration and inflammation. In the GalN model, both G-CSF and TAK-242, when used individually, reduced liver injury but their combination was significantly more effective. G-CSF treatment, with or without TAK-242, was associated with activation of the pro-regenerative and anti-apoptotic STAT3 pathway. LPS-driven ACLF was characterised by p21 overexpression, which is indicative of hepatic senescence and inhibition of hepatocyte regeneration. While TAK-242 treatment mitigated the effect on senescence, G-CSF, when co-administered with TAK-242, resulted in a significant increase in markers of hepatocyte regeneration. CONCLUSION: The combination of TAK-242 and G-CSF inhibits inflammation, promotes hepatic regeneration and prevents mortality in models of ACLF; thus, this combination could be a potential treatment option for ACLF. LAY SUMMARY: Acute-on-chronic liver failure is associated with severe liver inflammation and poor short-term survival. Therefore, effective treatments are urgently needed. Herein, we have shown, using mouse models, that the combination of granulocyte-colony stimulating factor (which can promote liver regeneration) and TAK-242 (which inhibits a receptor that plays a key role in inflammation) could be effective for the treatment of acute-on-chronic liver failure.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Engelmann C, Habtesion A, Hassan M, et al. Combination of G-CSF and a TLR4 inhibitor reduce inflammation and promote regeneration in a mouse model of ACLF. J Hepatol. 2022. PMID: 35843375. doi:10.1016/j.jhep.2022.07.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。